Radka Stoyanova

Professor and Director of Imaging and Biomarkers

University of Miami
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Radka Stoyanova is a Professor and Director of Imaging and Biomarkers at the University of Miami, USA. Her research primarily focuses on the applications of radiomics in prostate cancer radiotherapy and the analysis of dynamic susceptibility contrast (DSC)-MRI for segmenting tissue areas in stroke models. She is dedicated to advancing the understanding of imaging methodologies and their clinical implications in oncology and neurology.

Articles (3)

Purpose: Clinical risk grouping based on PSA, tumor grade, and disease extent guides treatment intensity for localized prostate cancer. However, many patients with intermediate- or high-risk disease treated with external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) still develop biochemical recurrence (BCR). Early identification of patients at high risk for BCR could enable personalized treatment strategies. Experimental Design: We prospectively enrolled 29 patients with intermediate- or high-risk prostate cancer undergoing EBRT and ADT. Pretreatment biopsies ( n = 60) underwent whole-transcriptome microarray and whole-exome sequencing. Patients received multiparametric MRI at baseline and 6 months after treatment, with a median follow-up of 6 years. Gene expression differences between patients with and without BCR were analyzed using pathway tools and validated in external datasets. A novel TGF-β gene signature was derived and tested across multiple cohorts (median follow-up: 5–11 years). Results: TGF-β activity was significantly associated with BCR in the discovery cohort ( P = 0.0081) and correlated with PTEN/TP53 alterations ( P = 0.0246) and baseline multiparametric MRI tumor volume ( P = 0.026). TGF-β activity also predicted metastasis-free survival ( P = 0.037) and, in an independent cohort ( n = 265), was prognostic for BCR-free ( P = 0.05), metastasis-free ( P P Conclusions: TGF-β activity is a dominant feature of intermediate- to unfavorable-risk prostate tumors prone to biochemical failure after EBRT with ADT and may serve as an independent prognostic biomarker beyond existing clinical criteria.

Year:

2025

Year:

2020

Year:

2020

Collaborators (8)

William A. Hall

-

UNITED STATES
View details

Bradford Wood

Adjunct Professor

University of Maryland

UNITED STATES
View details

Deborah Citrin

National Cancer Institute

UNITED STATES
View details

Adam Sowalsky

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Peter Choyke

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Peter Pinto

Principal Investigator, Chief Prostate Cancer Section

National Cancer Institute

UNITED STATES
View details

Rodrigo Delgadillo

University of Miami School of Medicine

UNITED STATES
View details

Melvin Chua

Professor (with Tenure)

Duke-NUS Medical School

SINGAPORE
View details